Choice of bronchodilator therapy for patients with COPD

New England Journal of Medicine

Volumn 364, Issue 12, 2011, Pages 1167-1168

  Wedzicha, Jadwiga A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID; INDACATEROL; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSPNEA; EDITORIAL; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; SIDE EFFECT; SPIROMETRY; TREATMENT OUTCOME;

EID: 79953198322     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1013932     Document Type: Editorial

References (12)

1. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96. (Pubitemid 47320802)
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: 2009 update. (http://www.goldcopd.com.)
3. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770-7. (Pubitemid 32881912)
4. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
5. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
6. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52. [Erratum, Thorax 2008;63:753.]
7. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31. (Pubitemid 41598207)
8. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study. Respir Res 2009;10:59.
9. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-8.
10. CG101 chronic obstructive pulmonary disease (update): full guideline. London: National Institute for Health and Clinical Excellence, 2010. (http://guidance.nice.org.uk/CG101/Guidance.)
11. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103.
12. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62.